When submitting an ANDA, generic drug manufacturers need to submit one of the following four statements in accordance with the provisions of the Orange Book.
Atom Bioscience, a biotech company specializing in innovative therapies for inflammation and metabolic diseases, announced FDA approval for the Phase 1 trial of its new drug, ABP-745.
Ubix Therapeutics Granted Green Light from FDA for Initial Clinical Trial of Oral Drug UBX-303-1, a BTK Inhibitor Aimed at Treating Resistant B-Cell Cancers.
Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements.
NKGen Biotech, Inc. declares the commencement of treatment in its initial participant within a Phase 1/2a Study using its own SNK01, aimed for moderate Alzheimer's Disease.
NeuroBo Pharma has filed an Investigational New Drug request with the FDA, seeking approval to commence a Phase 1 trial on compound DA-1726 aimed at combating obesity.
Clover Biopharmaceuticals reports positive initial findings from a phase I trial evaluating SCB-219M, an advanced bispecific Fc-fusion TPO-RA protein developed with CHO cell systems, focusing on safety, efficacy, and pharmacokinetics.